Dianthus Therapeutics (DNTH) Stock Price, News & Analysis

Company Overview

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Key Stats

• Today's Range: $36.16 to $38.59
• 50-Day Range: $18.25 to $37.90
• 52-Week Range: $13.36 to $38.59
• Volume: 1.17 million shs
• Average Volume: 862,952 shs
• Market Capitalization: $1.22 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.67
• Consensus Rating: Buy

Dianthus Therapeutics Stock Analysis - MarketRank™

Dianthus Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 549th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Dianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Dianthus Therapeutics has a consensus price target of $60.67, representing about 60.2% upside from its current price of $37.86.

Amount of Analyst Coverage

Dianthus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($2.61) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dianthus Therapeutics is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dianthus Therapeutics is -11.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dianthus Therapeutics has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

23.76% of the float of Dianthus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dianthus Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Dianthus Therapeutics has recently decreased by 6.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dianthus Therapeutics does not currently pay a dividend.

Dividend Growth

Dianthus Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

23.76% of the float of Dianthus Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Dianthus Therapeutics has a short interest ratio ("days to cover") of 10.9, which indicates bearish sentiment.

Change versus previous month

Short interest in Dianthus Therapeutics has recently decreased by 6.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.75

News Sentiment

Dianthus Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.07 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 35 news articles for Dianthus Therapeutics this week, compared to 4 articles on an average week.

Search Interest

11 people have searched for DNTH on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.

MarketBeat Follows

3 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $700,000.00 in company stock.

Percentage Held by Insiders

Only 8.15% of the stock of Dianthus Therapeutics is held by insiders.

Percentage Held by Institutions

47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DNTH Stock Analysis - Frequently Asked Questions

How have DNTH shares performed this year?

Dianthus Therapeutics' stock was trading at $21.80 at the beginning of the year. Since then, DNTH shares have increased by 73.7% and is now trading at $37.86.

How were Dianthus Therapeutics' earnings last quarter?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by $0.02. The firm had revenue of $0.19 million for the quarter, compared to analysts' expectations of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative trailing twelve-month return on equity of 34.72%.

Who are Dianthus Therapeutics' major shareholders?

Dianthus Therapeutics' top institutional shareholders include Vestal Point Capital LP (9.94%), Bain Capital Life Sciences Investors LLC (7.71%), Alliancebernstein L.P. (3.65%) and 5AM Venture Management LLC (3.06%). Insiders that own company stock include Fairmount Funds Management Llc, Simrat Randhawa and Ryan Savitz.
View institutional ownership trends.

How do I buy shares of Dianthus Therapeutics?

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Dianthus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Netflix (NFLX), Palo Alto Networks (PANW) and Invesco QQQ (QQQ).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/11/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DNTH
• CIK: 1690585
• Web: dianthustx.com
• Phone: 857-242-0170
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dianthus Therapeutics: $60.67
• High Price Target: $100.00
• Low Price Target: $40.00
• Potential Upside/Downside: +60.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.25)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$84.97 million
• Net Margins: -2,364.56%
• Pretax Margin: -2,364.60%
• Return on Equity: -34.72%
• Return on Assets: -32.72%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.12
• Quick Ratio: 13.12

Sales & Book Value

• Annual Sales: $6.24 million
• Price / Sales: 195.31
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 3.18

Miscellaneous

• Outstanding Shares: 32,190,000
• Free Float: 29,565,000
• Market Cap: $1.22 billion
• Optionable: Optionable
• Beta: 1.46